SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors react to a significant debt reduction move involving bond-for-equity exchanges alongside an extension for its 10-K filing. The community remains hyper-focused on the company's turnaround narrative and its substantial stake in Babcock & Wilcox, with many traders actively discussing the potential for a short squeeze as the market digests the balance sheet restructuring.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is in the spotlight as the community reacts to its recent FDA approval of Empaveli for the treatment of rare kidney diseases C3G and IC-MPGN, a major milestone that has sparked intense debate over the stock's future. Investors are heavily focused on whether this long-awaited regulatory win will serve as the necessary catalyst to reverse the company's recent downward trajectory and drive a meaningful growth turnaround.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following a strong quarterly earnings report that featured a revenue beat and upward-revised multi-year guidance driven by insatiable AI infrastructure demand. The stock is seeing heavy institutional interest as community sentiment aligns around the company's critical role in the data center buildout, with traders actively debating its path toward triple-digit price levels.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a central hub for intense retail speculation as the community aggressively promotes various meme coins and speculative projects while debating the asset's long-term resilience against broader macroeconomic volatility. Investors are actively sharing divergent views on whether the network represents a viable institutional-grade utility or a speculative environment prone to intense price swings and manipulation.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is seeing intense retail engagement and volatility as investors weigh the company's aggressive 10x revenue growth against its reliance on complex global supply chains and competitive solar headwinds. While the community remains divided over short-seller allegations regarding FEOC compliance and organizational stability, bulls are focused on the company's strategic domestic expansion and long-term potential as a critical player in the evolving AI-driven energy grid.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging on heavy volume following an initial production purchase order for Sonoma systems from a leading hyperscale data center customer, signaling a pivotal move into high-volume AI processor production. The community is actively debating the stock's potential for a massive rerating as shareholders look past recent revenue fluctuations, focusing instead on the company's expanding role as a critical gatekeeper for high-reliability AI hardware.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors digest news of a $75 million non-dilutive financing deal with Oberland Capital, which the community is interpreting as a major vote of confidence in the company's global expansion and revenue growth. While some participants are wary of volatility and the potential for short-term pressure, many long-term shareholders are expressing bullish sentiment, viewing the funding as a necessary step to stabilize the balance sheet and accelerate the rollout of their immunotherapy pipeline.

Maul Coin

Maul Coin is gaining rapid traction as a community-driven project, with investors actively discussing its potential for growth and the creator's transparency. The community is focused on pushing the token past bonding curve milestones and securing broader visibility through increased social media promotion.

TOYO Co. Ltd. engages in the design, manufacture, and sale of solar cells and modules. It is involved in integrating the upstream production of wafer and silicon, midstream production of solar cell, downstream production of photovoltaic (PV) modules, and potentially other stages of the solar power supply chain. The company was founded on November 8, 2022 and is headquartered in Tokyo, Japan.

TOYO Co Ltd.

TOYO Co., Ltd

TOYO is trending as investors digest the company's aggressive expansion and new US-based production initiatives, which are seen as a strategic hedge against solar import tariffs. Community members are actively debating the stock's significant valuation discount relative to peers, with many viewing the current price as an undervalued opportunity amid strong forward-looking growth projections.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant volatility as investors weigh the company's aggressive $8.5 billion infrastructure financing deal against broader market headwinds and persistent insider selling. While some traders view the recent dip as a tactical entry point bolstered by optimistic analyst price targets and institutional backing, others are concerned about debt leverage and the potential for a cooling AI sector.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apellis Pharmaceuticals Inc. (APLS) shares soared 140% in Tuesday’s pre-market trade after Biogen Inc. (BIIB) announced that it has agreed to acquire the company in a $5.6 billion deal.Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis Pharmaceuticals</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.Get updates to this developing story directly on Stocktwits.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artl-bfrg-hkit-stocks-top-premarket-gainers-march-31-2026/cZEPAT9RIV2">ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen

Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.

Equity

Frame 485.png

Get the daily email that keeps you tuned in and makes markets fun again.

cryptotwits - 800x800.png

Get the daily crypto email you’ll actually love to read. It's value-packed, data-driven, and seasoned with wit.

Frame 479.png

The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.

APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen

Latest News